

# Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B

Christopher Godina<sup>1</sup>, Michael N Pollak<sup>2</sup>, Helena Jernström<sup>1</sup>.

1 Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, SE-221 85 Lund, Sweden

2 Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Oncology, McGill University, Montreal, QC, Canada

## Table of Contents

Supplementary Figure Legends.....	2
Supplementary Figure 1.....	2
Supplementary Figure 2.....	3
Supplementary Table 1.....	4
Supplementary Table 2.....	5
Supplementary Table 3.....	6
Supplementary Table 4.....	7
Supplementary Table 5.....	8

Supplementary Table S6-9 is available separately as an .xlsx file (Additional File 1).


## Supplementary figure legends

**Supplementary Figure 1.** Flowchart of included and excluded patients in SCAN-B

**Supplementary Figure 2.** Molecular analyses of *IGFBP7* expression in I-SPY2 and SCAN-B


Volcano plots showing significantly up- and downregulated genes in *IGFBP7* Q4 compared to in *IGFBP7* Q1 tumors in (A) I-SPY2, and (B) SCAN-B. Dot plots showing activated and suppressed Hallmark Signatures in *IGFBP7* Q4 compared to in *IGFBP7* Q1 tumors in (C) I-SPY2, and (D) SCAN-B. (D).

**Supplementary Figure 1.**




# Supplementary Figure 2.


**A** IGFBP7 Q4 vs Q1 in I-SPY2, all patients




**B** IGFBP7 Q4 vs Q1 in SCAN-B, all patients



**C** Enriched Hallmarks in IGFBP7 Q4 vs Q1 in I-SPY2, all patients



**D** Enriched Hallmarks in IGFBP7 Q4 vs Q1 in SCAN-B, all patients



**Supplementary Table 1.** Descriptive statistics of IGFBP7 quartiles in relation to clinicopathological characteristics in I-SPY2

			IGFBP7 Quartiles			
	All patients <sup>1</sup>	Missing	Q1, n = 244 <sup>1</sup>	Q2, n = 244 <sup>1</sup>	Q3, n = 243 <sup>1</sup>	Q4, n = 243 <sup>1</sup>
<b>HR+</b>	528 (54%)	0	103 (42%)	133 (55%)	153 (63%)	139 (57%)
<b>HER2+</b>	244 (25%)	0	35 (14%)	71 (29%)	65 (27%)	73 (30%)
<b>MP2</b>	476 (49%)	0	168 (69%)	128 (52%)	97 (40%)	83 (34%)
<b>Immune+</b>	446 (46%)	0	140 (57%)	103 (42%)	101 (42%)	102 (42%)
<b>DRD+</b>	364 (37%)	3	128 (52%)	94 (39%)	71 (29%)	71 (29%)
<b>PAM50 Subtype</b>		15				
LumA	172 (18%)		16 (6.6%)	36 (15%)	57 (24%)	63 (26%)
Basal	406 (42%)		154 (64%)	100 (42%)	82 (34%)	70 (29%)
Her2	140 (15%)		27 (11%)	35 (15%)	34 (14%)	44 (18%)
LumB	218 (23%)		42 (17%)	66 (28%)	63 (26%)	47 (20%)
Normal	23 (2.4%)		2 (0.8%)	2 (0.8%)	3 (1.3%)	16 (6.7%)
<b>pCR</b>	313 (32%)	0	86 (35%)	74 (30%)	79 (33%)	74 (30%)
<b>Trial Arm</b>		0				
Control	205 (21%)		55 (23%)	45 (18%)	53 (22%)	52 (21%)
AMG386	133 (14%)		30 (12%)	37 (15%)	27 (11%)	39 (16%)
Ganetespib	93 (9.5%)		28 (11%)	22 (9.0%)	27 (11%)	16 (6.6%)
Ganitumab + metformin	105 (11%)		32 (13%)	29 (12%)	26 (11%)	18 (7.4%)
MK2206	94 (9.7%)		24 (9.8%)	17 (7.0%)	26 (11%)	27 (11%)
Neratinib	112 (11%)		24 (9.8%)	32 (13%)	28 (12%)	28 (12%)
Pembrolizumab	69 (7.1%)		8 (3.3%)	11 (4.5%)	16 (6.6%)	34 (14%)
Pertuzumab	44 (4.5%)		7 (2.9%)	19 (7.8%)	10 (4.1%)	8 (3.3%)
Trastuzumab-emtansine	52 (5.3%)		7 (2.9%)	17 (7.0%)	15 (6.2%)	13 (5.3%)
Carboplatin + ABT888	67 (6.9%)		29 (12%)	15 (6.1%)	15 (6.2%)	8 (3.3%)

<sup>1</sup>n (%)

Control: Paclitaxel (+Trastuzumab if HER2+) followed by Anthracyclines

Supplementary Table 2. Descriptive statistics of IGFBP7 quartiles in relation to clinicopathological characteristics in SCAN-B

		IGFBP7 Quartiles				
	All patients <sup>1</sup>	Missing	Q1, n = 1,332 <sup>1</sup>	Q2, n = 1,332 <sup>1</sup>	Q3, n = 1,331 <sup>1</sup>	Q4, N = 1,331 <sup>1</sup>
<b>Age at diagnosis, years</b>		0				
-40	270 (5.1%)		72 (5.4%)	51 (3.8%)	85 (6.4%)	62 (4.7%)
41-50	874 (16%)		176 (13%)	235 (18%)	260 (20%)	203 (15%)
51-60	1,045 (20%)		233 (17%)	253 (19%)	282 (21%)	277 (21%)
61-70	1,661 (31%)		396 (30%)	426 (32%)	403 (30%)	436 (33%)
71-80	995 (19%)		279 (21%)	249 (19%)	211 (16%)	256 (19%)
81-	481 (9.0%)		176 (13%)	118 (8.9%)	90 (6.8%)	97 (7.3%)
<b>Invasive tumor size (pT2/3/4)</b>	1,783 (35%)	166	530 (41%)	421 (32%)	403 (31%)	429 (33%)
<b>Lymph node status (pN1/2/3)</b>	1,873 (37%)	213	461 (36%)	475 (37%)	497 (39%)	440 (34%)
<b>Histological type</b>		37				
Ductal	4,182 (79%)		1,083 (82%)	1,085 (82%)	1,083 (82%)	931 (71%)
Lobular	732 (14%)		108 (8.2%)	137 (10%)	167 (13%)	320 (24%)
Other or Mixed	375 (7.1%)		131 (9.9%)	100 (7.6%)	77 (5.8%)	67 (5.1%)
<b>Histological grade</b>		382				
I	791 (16%)		130 (11%)	181 (15%)	224 (18%)	256 (21%)
II	2,443 (49%)		512 (42%)	621 (50%)	626 (50%)	684 (55%)
III	1,710 (35%)		588 (48%)	437 (35%)	391 (32%)	294 (24%)
<b>ER+</b>	4,497 (85%)	49	1,047 (79%)	1,138 (87%)	1,168 (88%)	1,144 (87%)
<b>PR+</b>	3,725 (71%)	51	871 (66%)	965 (73%)	959 (72%)	930 (71%)
<b>HER2+</b>	702 (14%)	149	145 (11%)	192 (15%)	213 (16%)	152 (12%)
<b>TNBC</b>	525 (10%)	278	208 (17%)	117 (9.3%)	91 (7.2%)	109 (8.6%)
<b>Endocrine therapy</b>	4,109 (78%)	85	965 (74%)	1,046 (79%)	1,053 (81%)	1,045 (80%)
<b>Chemotherapy</b>	2,243 (43%)	85	616 (47%)	583 (44%)	565 (43%)	479 (36%)
<b>Trastuzumab</b>	585 (11%)	85	118 (9.1%)	165 (13%)	172 (13%)	130 (9.9%)
<b>PAM50 Subtype</b>		0				
LumA	2,255 (42%)		365 (27%)	576 (43%)	650 (49%)	664 (50%)
Basal	471 (8.8%)		204 (15%)	114 (8.6%)	72 (5.4%)	81 (6.1%)
Her2	641 (12%)		131 (9.8%)	167 (13%)	193 (15%)	150 (11%)
LumB	1,275 (24%)		574 (43%)	391 (29%)	224 (17%)	86 (6.5%)
Normal	684 (13%)		58 (4.4%)	84 (6.3%)	192 (14%)	350 (26%)
<b>PAM50 ROR</b>		292				
High	2,361 (47%)		824 (66%)	674 (54%)	507 (40%)	356 (28%)
Intermediate	738 (15%)		205 (16%)	185 (15%)	204 (16%)	144 (11%)
Low	1,935 (38%)		219 (18%)	399 (32%)	554 (44%)	763 (60%)

<sup>1</sup>n (%)

**Supplementary Table 3** Odds ratio of achieving a pCR in relation *IGFBP7* gene expression, all patients (arms) in I-SPY2

Variable	IGFBP7 Continuous		IGFBP7 quartiles	
	OR <sup>1</sup>	95% CI <sup>1</sup>	OR <sup>1</sup>	95% CI <sup>1</sup>
<b>IGFBP7 Continuous</b>	0.99	0.79, 1.25		
<b>IGFBP7 Quartiles</b>				
Q1			Ref.	
Q2			0.77	0.50, 1.20
Q3			1.19	0.76, 1.85
Q4			0.96	0.60, 1.52
<b>HR+</b>	0.72	0.46, 1.10	0.71	0.46, 1.09
<b>HER2+</b>	3.32	1.88, 5.85	3.34	1.90, 5.90
<b>MP2</b>	1.54	0.97, 2.46	1.60	1.00, 2.56
<b>Immune+</b>	2.89	2.03, 4.15	2.88	2.02, 4.14
<b>DRD+</b>	1.64	1.03, 2.65	1.69	1.05, 2.73
<b>PAM50 Subtype</b>				
LumA	Ref.		Ref.	
Basal	1.86	0.83, 4.21	1.84	0.82, 4.17
Her2	3.32	1.70, 6.60	3.34	1.71, 6.65
LumB	1.58	0.86, 2.95	1.65	0.90, 3.09
Normal	2.00	0.59, 6.43	2.02	0.60, 6.50
<b>Trial Arm</b>				
Control	Ref.		Ref.	
AMG386	2.10	1.19, 3.73	2.15	1.22, 3.82
Ganetespib	1.74	0.91, 3.28	1.69	0.89, 3.20
Ganitumab + metformin	1.76	0.92, 3.32	1.75	0.92, 3.30
MK2206	1.89	1.01, 3.54	1.85	0.99, 3.47
Neratinib	1.98	1.08, 3.64	2.01	1.10, 3.70
Pembrolizumab	5.38	2.70, 10.8	5.30	2.66, 10.7
Pertuzumab	4.91	2.09, 11.8	5.21	2.20, 12.6
Trastuzumab-emtansine	3.82	1.65, 8.99	3.94	1.69, 9.32
Carboplatin + ABT888	3.55	1.80, 7.04	3.56	1.80, 7.06

<sup>1</sup>OR = Odds Ratio, CI = Confidence Interval

Control: Paclitaxel (+Trastuzumab if HER2+) followed by doxorubicin and cyclophosphamide

**Supplementary Table 4.** *IGFBP7* (in quartiles) gene expression in relation to clinical outcome in SCAN-B

Variables	Recurrence-free interval		Distant metastasis-free interval	
	HR <sup>1</sup>	95% CI <sup>1</sup>	HR <sup>1</sup>	95% CI <sup>1</sup>
<b>Crude</b>				
<b>IGFBP7 Quartiles</b>				
Q1	Ref.		Ref.	
Q2	0.95	0.75, 1.21	0.99	0.76, 1.31
Q3	0.92	0.72, 1.16	0.93	0.71, 1.23
Q4	0.96	0.76, 1.22	1.00	0.77, 1.32
<b>Multivariable</b>				
<b>IGFBP7 Quartiles</b>				
Q1	Ref.		Ref.	
Q2	1.13	0.87, 1.47	1.26	0.93, 1.71
Q3	1.20	0.91, 1.58	1.37	1.00, 1.89
Q4	1.37	1.04, 1.82	1.60	1.15, 2.22
<b>Age (5-year bin)</b>	1.00	0.99, 1.01	1.01	1.00, 1.02
<b>Tumor size (pT2/3/4)</b>	1.90	1.55, 2.32	2.26	1.78, 2.85
<b>Lymph node status (pN1/2/3)</b>	1.31	1.06, 1.62	1.57	1.24, 2.01
<b>Grade III</b>	1.27	0.98, 1.63	1.29	0.97, 1.73
<b>ER+</b>	1.52	0.94, 2.46	1.06	0.59, 1.91
<b>PR+</b>	0.90	0.69, 1.17	0.81	0.60, 1.09
<b>HER2+</b>	1.95	1.27, 2.99	2.09	1.32, 3.30
<b>PAM50 ROR High</b>	2.20	1.61, 3.01	2.47	1.71, 3.58
<b>PAM50 subtype</b>				
LumA	Ref.		Ref.	
Basal	1.53	0.91, 2.58	1.68	0.93, 3.04
Her2	1.60	1.06, 2.42	1.58	0.99, 2.53
LumB	1.21	0.87, 1.70	1.29	0.87, 1.90
Normal	1.40	0.99, 1.97	1.47	0.97, 2.23
<b>Chemotherapy</b>	0.77	0.59, 1.00	0.91	0.67, 1.24
<b>Endocrine therapy</b>	0.45	0.32, 0.63	0.75	0.46, 1.21
<b>Trastuzumab</b>	0.30	0.18, 0.51	0.29	0.16, 0.51

**Supplementary Table 5.** *IGFBP7* (continuous) gene expression in relation to clinical outcome in SCAN-B

Variables	Recurrence-free interval		Distant metastasis-free interval	
	HR <sup>1</sup>	95% CI <sup>1</sup>	HR <sup>1</sup>	95% CI <sup>1</sup>
<b>Crude</b>				
<b>IGFBP7 Continuous</b>	1.01	0.88, 1.16	1.02	0.87, 1.20
<b>Multivariable</b>				
<b>IGFBP7 Continuous</b>	1.29	1.09, 1.53	1.41	1.16, 1.73
<b>Age (5-year bin)</b>	1.00	0.99, 1.01	1.01	1.00, 1.02
<b>Tumor size (pT2/3/4)</b>	1.92	1.57, 2.34	2.27	1.80, 2.87
<b>Lymph node status (pN1/2/3)</b>	1.30	1.05, 1.60	1.56	1.23, 1.99
<b>Grade III</b>	1.27	0.99, 1.63	1.29	0.97, 1.73
<b>ER+</b>	1.52	0.94, 2.46	1.05	0.58, 1.91
<b>PR+</b>	0.90	0.69, 1.18	0.81	0.61, 1.09
<b>HER2+</b>	1.92	1.25, 2.93	2.07	1.31, 3.26
<b>PAM50 ROR High</b>	2.23	1.63, 3.05	2.52	1.74, 3.64
<b>PAM50 subtype</b>				
LumA	Ref.		Ref.	
Basal	1.57	0.93, 2.65	1.72	0.95, 3.11
Her2	1.61	1.07, 2.43	1.59	0.99, 2.55
LumB	1.24	0.89, 1.73	1.31	0.89, 1.93
Normal	1.37	0.97, 1.93	1.43	0.94, 2.17
<b>Chemotherapy</b>	0.77	0.59, 1.00	0.91	0.67, 1.24
<b>Endocrine therapy</b>	0.45	0.32, 0.63	0.75	0.46, 1.21
<b>Trastuzumab</b>	0.31	0.18, 0.52	0.29	0.17, 0.52